Comprehensive Optimization of a Freeze-Drying Process Achieving Enhanced Long-Term Stability and In Vivo Performance of Lyophilized MRNA-LNPs

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39408932

Authors

Teresa Alejo

Alfonso Toro-Cordova

Laura Fernandez

Andrea Rivero

Andrei Mihai Stoian

Luna Perez

Victor Navarro

Juan Martinez-Olivan

Diego de Miguel

Affiliations

Soon will be listed here.

Abstract

The success of mRNA vaccines against SARS-CoV-2 has prompted interest in mRNA-based pharmaceuticals due to their rapid production, adaptability, and safety. Despite these advantages, the inherent instability of mRNA and its rapid degradation in vivo underscores the need for an encapsulation system for the administration and delivery of RNA-based therapeutics. Lipid nanoparticles (LNPs) have proven the most robust and safest option for in vivo applications. However, the mid- to long-term storage of mRNA-LNPs still requires sub-zero temperatures along the entire chain of supply, highlighting the need to develop alternatives to improve mRNA vaccine stability under non-freezing conditions to facilitate logistics and distribution. Lyophilization presents itself as an effective alternative to prolong the shelf life of mRNA vaccines under refrigeration conditions, although a complex optimization of the process parameters is needed to maintain the integrity of the mRNA-LNPs. Recent studies have demonstrated the feasibility of freeze-drying LNPs, showing that lyophilized mRNA-LNPs retain activity and stability. However, long-term functional data remain limited. Herein, we focus on obtaining an optimized lyophilizable mRNA-LNP formulation through the careful selection of an optimal buffer and cryoprotectant and by tuning freeze-drying parameters. The results demonstrate that our optimized lyophilization process maintains LNP characteristics and functionality for over a year at refrigerated temperatures, offering a viable solution to the logistical hurdles of mRNA vaccine distribution.

References

Suzuki Y, Miyazaki T, Muto H, Kubara K, Mukai Y, Watari R . Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Mol Ther Nucleic Acids. 2022; 30:226-240. PMC: 9508692. DOI: 10.1016/j.omtn.2022.09.017. View

Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z . Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023; 9(1):9. PMC: 9868121. DOI: 10.1038/s41421-022-00517-9. View

Hald Albertsen C, Kulkarni J, Witzigmann D, Lind M, Petersson K, Simonsen J . The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022; 188:114416. PMC: 9250827. DOI: 10.1016/j.addr.2022.114416. View

Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078-1094. PMC: 8353930. DOI: 10.1038/s41578-021-00358-0. View

Gatto M, Najahi-Missaoui W . Lyophilization of Nanoparticles, Does It Really Work? Overview of the Current Status and Challenges. Int J Mol Sci. 2023; 24(18). PMC: 10530935. DOI: 10.3390/ijms241814041. View

Verbeke R, Lentacker I, De Smedt S, Dewitte H . The dawn of mRNA vaccines: The COVID-19 case. J Control Release. 2021; 333:511-520. PMC: 8008785. DOI: 10.1016/j.jconrel.2021.03.043. View

Leung A, Hafez I, Baoukina S, Belliveau N, Zhigaltsev I, Afshinmanesh E . Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces. 2012; 116(34):18440-18450. PMC: 3434764. DOI: 10.1021/jp303267y. View

Martinez J, Lampaya V, Larraga A, Magallon H, Casabona D . Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction. Front Mol Biosci. 2023; 10:1248511. PMC: 10570549. DOI: 10.3389/fmolb.2023.1248511. View

Oude Blenke E, Ornskov E, Schoneich C, Nilsson G, Volkin D, Mastrobattista E . The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case. J Pharm Sci. 2022; 112(2):386-403. PMC: 9637289. DOI: 10.1016/j.xphs.2022.11.001. View

10.

Thorat A, Suryanarayanan R . Characterization of Phosphate Buffered Saline (PBS) in Frozen State and after Freeze-Drying. Pharm Res. 2019; 36(7):98. DOI: 10.1007/s11095-019-2619-2. View

11.

Jung H, Lee S, Lee S, Youn H, Im H . Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of imaging. Theranostics. 2022; 12(17):7509-7531. PMC: 9691360. DOI: 10.7150/thno.77259. View

12.

Packer M, Gyawali D, Yerabolu R, Schariter J, White P . A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun. 2021; 12(1):6777. PMC: 8608879. DOI: 10.1038/s41467-021-26926-0. View

13.

Henderson M, Eygeris Y, Jozic A, Herrera M, Sahay G . Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles. Mol Pharm. 2022; 19(11):4275-4285. PMC: 9916253. DOI: 10.1021/acs.molpharmaceut.2c00587. View

14.

Cheng M, Leung J, Zhang Y, Strong C, Basha G, Momeni A . Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency. Adv Mater. 2023; 35(31):e2303370. DOI: 10.1002/adma.202303370. View

15.

Szabo G, Mahiny A, Vlatkovic I . COVID-19 mRNA vaccines: Platforms and current developments. Mol Ther. 2022; 30(5):1850-1868. PMC: 8856755. DOI: 10.1016/j.ymthe.2022.02.016. View

16.

Abdelwahed W, Degobert G, Stainmesse S, Fessi H . Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006; 58(15):1688-713. DOI: 10.1016/j.addr.2006.09.017. View

17.

Meulewaeter S, Nuytten G, Cheng M, De Smedt S, Cullis P, Beer T . Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J Control Release. 2023; 357:149-160. PMC: 10062427. DOI: 10.1016/j.jconrel.2023.03.039. View

18.

Degobert G, Aydin D . Lyophilization of Nanocapsules: Instability Sources, Formulation and Process Parameters. Pharmaceutics. 2021; 13(8). PMC: 8400524. DOI: 10.3390/pharmaceutics13081112. View

19.

Schoenmaker L, Witzigmann D, Kulkarni J, Verbeke R, Kersten G, Jiskoot W . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601:120586. PMC: 8032477. DOI: 10.1016/j.ijpharm.2021.120586. View

20.

Trenkenschuh E, Friess W . Freeze-drying of nanoparticles: How to overcome colloidal instability by formulation and process optimization. Eur J Pharm Biopharm. 2021; 165:345-360. DOI: 10.1016/j.ejpb.2021.05.024. View